For the second time, Besta Med is recognized for its innovative products at the largest pharmaceutical forum in our country
The innovative and unique migraine medication, Avoran®, has been chosen as the Product of the Year in the Prescription Medication category for its optimized effect based on its pharmacokinetic properties. The prestigious award for Avoran® was presented by the Product of the Year Selection Commission of the Bulgarian Pharmaceutical Union during the official ceremony at the largest pharmaceutical forum in our country, the Bulgarian Pharmaceutical Days, held from June 23rd to 25th in Borovets.
Avoran® is the newest product of Besta Med, used for the treatment of migraines with or without aura, and currently has no analogue on the Bulgarian market.
The team at Besta Med stated from the stage upon receiving the award that this recognition is a significant acknowledgement for them, demonstrating the long journey they have traveled together. They emphasized that the award they received today is evidence of the understanding, collaboration, and mutual support between healthcare professionals and the responsible and developing business they represent. The team expressed their belief that they will continue to do their best for the patients, together with Bulgarian pharmacists.
Milena Ivanova, the CEO of Besta Med, is definite that the company will continue to invest in innovative solutions, creating products with the spirit, contribution, and significance of Avoran® in the name of human health and quality of life. “Our unwavering goal will continue to be providing strategic solutions to assist patients in Bulgaria and our partners,” emphasized Milena Ivanova.
For the second time, the pharmaceutical company Besta Med receives a prestigious award for its medicinal product, following the combination of ibuprofen with L-arginine in Oklys® winning first place in the category of “Non-prescription Medicinal Product for Technological Innovation in Medicinal Form” in 2021.